Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
72.14 USD | -0.47% | -3.53% | +0.97% |
Business Summary
- molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin;
- breast health (35.5%): digital mammography and breast biopsy solutions and systems;
- gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures;
- bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment.
Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%).
Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).
Number of employees: 6,990
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Diagnostics
46.6
%
| 3,019 | 62.1 % | 1,880 | 46.6 % | -37.71% |
Breast Health
35.5
%
| 1,228 | 25.2 % | 1,433 | 35.5 % | +16.69% |
GYN Surgical
15.0
%
| 523 | 10.8 % | 604 | 15.0 % | +15.55% |
Skeletal Health
2.8
%
| 94 | 1.9 % | 113 | 2.8 % | +21.15% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
75.9
%
| 3,468 | 71.3 % | 3,058 | 75.9 % | -11.82% |
Europe
12.9
%
| 889 | 18.3 % | 520 | 12.9 % | -41.44% |
Asia-Pacific
6.3
%
| 360 | 7.4 % | 256 | 6.3 % | -28.91% |
Rest of the World
4.9
%
| 147 | 3.0 % | 196 | 4.9 % | +33.88% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 13-12-06 | |
Karleen Oberton
DFI | Director of Finance/CFO | 54 | 05-12-31 |
Essex Mitchell
COO | Chief Operating Officer | 44 | 17-08-31 |
Paul Malenchini
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Lisa Hellman
IRO | Public Communications Contact | - | 21-05-31 |
Francis Pruell
IRC | Investor Relations Contact | - | - |
Ryan Simon
IRO | Public Communications Contact | - | 14-07-31 |
Benjamin Cohn
AUD | Comptroller/Controller/Auditor | - | 18-08-02 |
Corporate Officer/Principal | - | - | |
Corporate Officer/Principal | - | 23-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 13-12-06 | |
Director/Board Member | 69 | 17-05-14 | |
Director/Board Member | 63 | 16-11-30 | |
Director/Board Member | 53 | 11-10-31 | |
Sally Crawford
BRD | Director/Board Member | 70 | 07-10-21 |
Scott Garrett
BRD | Director/Board Member | 74 | 13-05-05 |
Stacey Stewart
BRD | Director/Board Member | 60 | 23-01-01 |
Ludwig Hantson
BRD | Director/Board Member | 61 | 18-11-20 |
Nanaz Mohtashami
BRD | Director/Board Member | 46 | 23-09-19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 300,756,948 | 231,703,789 ( 77.04 %) | 67,380,000 ( 22.40 %) | 77.04 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Diagenode SA
Diagenode SA Medical SpecialtiesHealth Technology Diagenode SA provides solutions for epigenetics research, biological sample preparation, and diagnostics assays. It offers Bioruptor® shearing and IP-Star® automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company was founded in 2003 and is headquartered in Seraing, Belgium. |
Medical Specialties
|
Hologic HUB Ltd.
Hologic HUB Ltd. Medical DistributorsDistribution Services Part of Hologic, Inc., Hologic HUB Ltd. is a healthcare product distributor. The company is based in Manchester, UK. Founded in 2015, Hologic HUB distributes healthcare products. |
Medical Distributors
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.97% | 16.84B | |
+7.88% | 219B | |
+10.23% | 189B | |
+25.36% | 150B | |
+33.13% | 113B | |
+2.97% | 65.05B | |
+14.98% | 52.83B | |
+1.91% | 49.39B | |
-6.09% | 38.1B | |
-0.43% | 35.14B |
- Stock Market
- Equities
- HOLX Stock
- Company Hologic, Inc.